Oklo Inc. (NYSE:OKLO) just proved it can build a nuclear reactor as fast as it promised. On August 6, the company announced its Groves Isotope Test Reactor in Lockhart, Texas, achieved first criticality, a controlled, self-sustaining nuclear chain reaction, less than a year after groundbreaking. It's the first project under the US Department of Energy's Reactor Pilot Program to reach criticality on private land from a greenfield site, and Oklo says it may be the fastest privately funded, privately sited reactor build in history.
CEO Jacob DeWitte called it "an incredible milestone for our team," noting Oklo built Groves from raw land, handled the civil excavation and construction itself, and manufactured or procured every component, including fuel, in-house. On the company's August 7 earnings call, management put the timeline at under 11 months from greenfield to criticality. Groves is meant to anchor Oklo's isotope business, supplying materials for healthcare, industry, research, ******* e, and national security, with revenue expected to begin in the first half of 2027 out of a commercial Idaho radiochemistry lab.
Management says the engineering practices, training programs, and commissioning experience from Groves should reduce execution risk across the company's future isotope, powerhouse, and fuel cycle projects. The balance sheet backs that ambition, with $3 billion in cash and marketable securities on hand after Oklo raised $1.9 billion in 2026 through its at-the-market programs. The broader pipeline kept moving too, with Aurora-INL site excavation nearly complete and a Kiewit memorandum of understanding advancing the 1.2-gigawatt Ohio Power Campus that will supply Meta. Shares jumped more than 10% on August 7, the day after the update, coinciding with the earnings report.
The milestone came alongside a bigger bill. Oklo reported a net loss of $81.6 million for the quarter, with an operating loss of $124.2 million, and the company still has no forward price-to-earnings ratio because it isn't yet profitable. Management raised its 2026 operating cash flow guidance to $120 million to $150 million, up from $80 million to $100 million, and lifted capital expenditure guidance to $400 million to $500 million from $350 million to $450 million, both tied to accelerated procurement for Aurora-INL and opportunistic fuel purchases. Groves itself is also a test reactor for isotopes, not Oklo's commercial power business. The Aurora-INL project that would validate the company's powerhouse platform isn't targeted to start up until 2028, and the first phase of the Aurora-Ohio powerhouse meant to supply Meta's data centers isn't expected until early 2030.
#aurora #first #isotope
CEO Jacob DeWitte called it "an incredible milestone for our team," noting Oklo built Groves from raw land, handled the civil excavation and construction itself, and manufactured or procured every component, including fuel, in-house. On the company's August 7 earnings call, management put the timeline at under 11 months from greenfield to criticality. Groves is meant to anchor Oklo's isotope business, supplying materials for healthcare, industry, research, ******* e, and national security, with revenue expected to begin in the first half of 2027 out of a commercial Idaho radiochemistry lab.
Management says the engineering practices, training programs, and commissioning experience from Groves should reduce execution risk across the company's future isotope, powerhouse, and fuel cycle projects. The balance sheet backs that ambition, with $3 billion in cash and marketable securities on hand after Oklo raised $1.9 billion in 2026 through its at-the-market programs. The broader pipeline kept moving too, with Aurora-INL site excavation nearly complete and a Kiewit memorandum of understanding advancing the 1.2-gigawatt Ohio Power Campus that will supply Meta. Shares jumped more than 10% on August 7, the day after the update, coinciding with the earnings report.
The milestone came alongside a bigger bill. Oklo reported a net loss of $81.6 million for the quarter, with an operating loss of $124.2 million, and the company still has no forward price-to-earnings ratio because it isn't yet profitable. Management raised its 2026 operating cash flow guidance to $120 million to $150 million, up from $80 million to $100 million, and lifted capital expenditure guidance to $400 million to $500 million from $350 million to $450 million, both tied to accelerated procurement for Aurora-INL and opportunistic fuel purchases. Groves itself is also a test reactor for isotopes, not Oklo's commercial power business. The Aurora-INL project that would validate the company's powerhouse platform isn't targeted to start up until 2028, and the first phase of the Aurora-Ohio powerhouse meant to supply Meta's data centers isn't expected until early 2030.
#aurora #first #isotope
2 hours ago
